Ibogaine, 5-MeO-DMT Adverse Outcomes: US Survey Insights

Ibogaine and 5-MeO-DMT Show Highest Rates of Adverse Outcomes

A nationally representative survey of 1,964 U.S. adults, published September 20, 2026 in JAMA Network Open, reports that ibogaine and 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine) are associated with the most frequent self-reported adverse outcomes among commonly used psychedelics. While psilocybin, LSD (lysergic acid diethylamide), and MDMA (methylenedioxymethamphetamine) accounted for the greatest absolute number of adverse reports due to their higher prevalence of use, the proportion of users reporting adverse outcomes was highest for ibogaine and 5-MeO-DMT. The study, led by Otto Simonsson, Ph.D., provides new data points for clinicians, researchers, and regulators as psychedelic substances move from underground use into formal clinical evaluation.

Mechanisms and Context: Cardiac Risks and Use Patterns

Ibogaine's known association with cardiac adverse effects, particularly QTc prolongation and arrhythmia, is reinforced by the survey's findings. The survey's results align with prior case reports and small studies that have highlighted the potential for life-threatening arrhythmias following ibogaine ingestion. 5-MeO-DMT, a potent tryptamine, is less well studied but has been linked to acute psychological distress and, in rare cases, seizures or loss of consciousness. The survey included 1,151 respondents reporting past-year psilocybin use, 376 for LSD, 539 for MDMA, 74 for ibogaine, and 95 for 5-MeO-DMT. The relatively small sample sizes for ibogaine and 5-MeO-DMT users mean the findings should be interpreted with caution, but the elevated rates of adverse outcomes are consistent with mechanistic concerns and case literature. Notably, the survey design does not allow for causal inference, but it does provide a population-level snapshot of relative risk perceptions and experiences.

Clinical and Regulatory Implications

The survey's findings are highly relevant as psychedelics such as psilocybin, LSD, and MDMA advance through Phase 2 and Phase 3 clinical trials for psychiatric disorders in the United States and internationally. Ibogaine and 5-MeO-DMT, while less prevalent in clinical research, are being investigated in smaller trials for substance use disorders and mood disorders. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and Health Canada have previously flagged cardiac safety as a key concern for ibogaine, requiring comprehensive cardiac screening and monitoring in investigational new drug (IND) protocols. This survey adds weight to those requirements and highlights the need for robust exclusion criteria and monitoring protocols in future trials, especially for substances with known or suspected cardiotoxicity. For 5-MeO-DMT, the data underscore the importance of screening for psychiatric risk factors and establishing clear protocols for managing acute psychological and physiological reactions.

• Concrete example: In 2023, a Phase 1 ibogaine trial in the UK (ISRCTN16467538) was paused after a participant experienced asymptomatic QTc prolongation, illustrating the real-world impact of these risk signals on trial design and regulatory oversight.

Risks, Unknowns, and Survey Limitations

The primary limitation of the study is its cross-sectional, self-reported design, which precludes causal attribution and may be influenced by recall bias or underreporting. Additionally, adverse outcomes were not medically verified, and the severity and duration of reported events were not systematically captured. Nevertheless, the findings provide a valuable risk signal for substances that are often discussed in the context of therapeutic potential but have not undergone the same level of rigorous safety evaluation as more established compounds. The survey also does not account for the context of use (e.g., recreational, ceremonial, clinical), which can significantly influence both the likelihood and severity of adverse outcomes. Importantly, the data reinforce the need for post-marketing surveillance and real-world evidence collection should these substances receive regulatory approval for medical use.

Looking Forward: Balancing Promise and Precaution

As the psychedelic research and regulatory landscape evolves, the new survey data call for a balanced approach that weighs both the promise and the risks of emerging compounds. For researchers and sponsors designing future trials, integrating systematic cardiac and psychiatric screening, real-time monitoring, and robust adverse event reporting will be essential. For policymakers and regulators, these findings highlight the need for clear guidance on risk mitigation, informed consent, and post-approval surveillance. For clinicians, the results underscore the importance of patient education and individualized risk assessment. As more data emerge from both controlled trials and real-world use, the field will need to continually update its understanding of the safety profiles of both established and novel psychedelics. The path forward will require not only scientific rigor but also humility in the face of persistent uncertainties.

How we research: This article was written and reviewed by Dr. Alex Turner, PhD (Neuroscience), on 2026-10-18. Primary sources include the original JAMA Network Open publication (OpenAlex W7222604653) and clinical trial registries.